End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11,691 ARS | -1.82% | -8.88% | +15.36% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's enterprise value to sales, at 3.85 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.36% | 348B | - | ||
+39.82% | 731B | C+ | ||
+31.34% | 586B | B | ||
+14.23% | 319B | B- | ||
+0.86% | 273B | C+ | ||
+13.47% | 235B | B+ | ||
-6.63% | 203B | A+ | ||
+7.49% | 202B | B- | ||
+4.51% | 159B | C+ | ||
-2.05% | 158B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson